Acute hypoxemic respiratory failure in immunocompromised patients: the Efraim multinational prospective cohort study

Abstract

Background

In immunocompromised patients with acute hypoxemic respiratory failure (ARF), initial management aims primarily to avoid invasive mechanical ventilation (IMV).

Methods

To assess the impact of initial management on IMV and mortality rates, we performed a multinational observational prospective cohort study in 16 countries (68 centers).

Results

A total of 1611 patients were enrolled (hematological malignancies 51.9%, solid tumors 35.2%, systemic diseases 17.3%, and solid organ transplantation 8.8%). The main ARF etiologies were bacterial (29.5%), viral (15.4%), and fungal infections (14.7%), or undetermined (13.2%). On admission, 915 (56.8%) patients were not intubated. They received standard oxygen (N = 496, 53.9%), high-flow oxygen (HFNC, N = 187, 20.3%), noninvasive ventilation (NIV, N = 153, 17.2%), and NIV + HFNC (N = 79, 8.6%). Factors associated with IMV included age (hazard ratio = 0.92/year, 95% CI 0.86–0.99), day-1 SOFA (1.09/point, 1.06–1.13), day-1 PaO2/FiO2 (1.47, 1.05–2.07), ARF etiology (Pneumocystis jirovecii pneumonia (2.11, 1.42–3.14), invasive pulmonary aspergillosis (1.85, 1.21–2.85), and undetermined cause (1.46, 1.09–1.98). After propensity score matching, HFNC, but not NIV, had an effect on IMV rate (HR = 0.77, 95% CI 0.59–1.00, p = 0.05). ICU, hospital, and day-90 mortality rates were 32.4, 44.1, and 56.4%, respectively. Factors independently associated with hospital mortality included age (odds ratio = 1.18/year, 1.09–1.27), direct admission to the ICU (0.69, 0.54–0.87), day-1 SOFA excluding respiratory score (1.12/point, 1.08–1.16), PaO2/FiO2 < 100 (1.60, 1.03–2.48), and undetermined ARF etiology (1.43, 1.04–1.97). Initial oxygenation strategy did not affect mortality; however, IMV was associated with mortality, the odds ratio depending on IMV conditions: NIV + HFNC failure (2.31, 1.09–4.91), first-line IMV (2.55, 1.94–3.29), NIV failure (3.65, 2.05–6.53), standard oxygen failure (4.16, 2.91–5.93), and HFNC failure (5.54, 3.27–9.38).

Conclusion

HFNC has an effect on intubation but not on mortality rates. Failure to identify ARF etiology is associated with higher rates of both intubation and mortality. This suggests that in addition to selecting the appropriate oxygenation device, clinicians should strive to identify the etiology of ARF.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. 1.

    Harpaz R, Dahl RM, Dooling KL (2016) Prevalence of immunosuppression among US adults, 2013. JAMA 316(23):2547–2548

    Article  PubMed  Google Scholar 

  2. 2.

    Fernandez-Ruiz M, Kumar D, Humar A (2014) Clinical immune-monitoring strategies for predicting infection risk in solid organ transplantation. Clin Transl Immunol 3(2):e12

    CAS  Article  Google Scholar 

  3. 3.

    Winthrop KL, Novosad SA, Baddley JW et al (2015) Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance. Ann Rheum Dis 74(12):2107–2116

    CAS  Article  PubMed  Google Scholar 

  4. 4.

    Azoulay E, Pene F, Darmon M et al (2015) Managing critically ill hematology patients: time to think differently. Blood Rev 29(6):359–367

    Article  PubMed  Google Scholar 

  5. 5.

    Puxty K, McLoone P, Quasim T, Sloan B, Kinsella J, Morrison DS (2015) Risk of critical illness among patients with solid cancers: a population-based observational study. JAMA Oncol 1(8):1078–1085

    Article  PubMed  Google Scholar 

  6. 6.

    Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67(1):7–30

    Article  PubMed  Google Scholar 

  7. 7.

    Morrison VA (2014) Immunosuppression associated with novel chemotherapy agents and monoclonal antibodies. Clin Infect Dis 59(Suppl 5):S360–S364

    CAS  Article  PubMed  Google Scholar 

  8. 8.

    Novosad SA, Winthrop KL (2014) Beyond tumor necrosis factor inhibition: the expanding pipeline of biologic therapies for inflammatory diseases and their associated infectious sequelae. Clin Infect Dis 58(11):1587–1598

    CAS  Article  PubMed  Google Scholar 

  9. 9.

    Canet E, Zafrani L, Azoulay E (2016) The critically ill kidney transplant recipient: a narrative review. Chest 149(6):1546–1555

    Article  PubMed  Google Scholar 

  10. 10.

    Dumas G, Geri G, Montlahuc C et al (2015) Outcomes in critically ill patients with systemic rheumatic disease: a multicenter study. Chest 148(4):927–935

    Article  PubMed  Google Scholar 

  11. 11.

    Frat JP, Ragot S, Girault C et al (2016) Effect of non-invasive oxygenation strategies in immunocompromised patients with severe acute respiratory failure: a post hoc analysis of a randomised trial. Lancet Respir Med 4(8):646–652

    Article  PubMed  Google Scholar 

  12. 12.

    Lemiale V, Resche-Rigon M, Mokart D et al (2017) High-flow nasal cannula oxygenation in immunocompromised patients with acute hypoxemic respiratory failure: a Groupe de Recherche Respiratoire en Reanimation Onco-Hematologique Study. Crit Care Med 45(3):e274–e280

    Article  PubMed  Google Scholar 

  13. 13.

    Mokart D, Geay C, Chow-Chine L et al (2016) High-flow oxygen therapy in cancer patients with acute respiratory failure. Intensive Care Med 41(11):2008–2010

    Article  Google Scholar 

  14. 14.

    Lemiale V, Mokart D, Resche-Rigon M et al (2015) Effect of noninvasive ventilation vs oxygen therapy on mortality among immunocompromised patients with acute respiratory failure: a randomized clinical trial. JAMA 314(16):1711–1719

    CAS  Article  PubMed  Google Scholar 

  15. 15.

    Papazian L, Corley A, Hess D et al (2016) Use of high-flow nasal cannula oxygenation in ICU adults: a narrative review. Intensive Care Med 42(9):1336–1349

    CAS  Article  PubMed  Google Scholar 

  16. 16.

    Mokart D, Lambert J, Schnell D et al (2013) Delayed intensive care unit admission is associated with increased mortality in patients with cancer with acute respiratory failure. Leuk Lymphoma 54(8):1724–1729

    Article  PubMed  Google Scholar 

  17. 17.

    Burghi G, Lemiale V, Seguin A et al (2011) Outcomes of mechanically ventilated hematology patients with invasive pulmonary aspergillosis. Intensive Care Med 37(10):1605–1612

    Article  PubMed  Google Scholar 

  18. 18.

    Contejean A, Lemiale V, Resche-Rigon M et al (2017) Increased mortality in hematological malignancy patients with acute respiratory failure from undetermined etiology: a Groupe de Recherche en Reanimation Respiratoire en Onco-Hematologique (Grrr-OH) study. Ann Intensive Care 6(1):102

    Article  Google Scholar 

  19. 19.

    Azoulay E, Mokart D, Pene F et al (2013) Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium—a groupe de recherche respiratoire en reanimation onco-hematologique study. J Clin Oncol 31(22):2810–2818

    Article  PubMed  Google Scholar 

  20. 20.

    Azoulay E, Lemiale V, Mokart D et al (2014) Acute respiratory distress syndrome in patients with malignancies. Intensive Care Med 40(8):1106–1114

    Article  PubMed  Google Scholar 

  21. 21.

    Adda M, Coquet I, Darmon M, Thiery G, Schlemmer B, Azoulay E (2008) Predictors of noninvasive ventilation failure in patients with hematologic malignancy and acute respiratory failure. Crit Care Med 36(10):2766–2772

    Article  PubMed  Google Scholar 

  22. 22.

    Gristina GR, Antonelli M, Conti G et al (2011) Noninvasive versus invasive ventilation for acute respiratory failure in patients with hematologic malignancies: a 5-year multicenter observational survey. Crit Care Med 39(10):2232–2239

    Article  PubMed  Google Scholar 

  23. 23.

    Azoulay E, Mokart D, Lambert J et al (2010) Diagnostic strategy for hematology and oncology patients with acute respiratory failure: randomized controlled trial. Am J Respir Crit Care Med 182(8):1038–1046

    Article  PubMed  Google Scholar 

  24. 24.

    Vincent JL, Moreno R, Takala J et al (1996) The SOFA (Sepsis-related organ failure assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 22(7):707–710

    CAS  Article  PubMed  Google Scholar 

  25. 25.

    Del Sorbo L, Ranieri VM, Ferguson ND (2016) The Berlin definition met our needs: yes. Intensive Care Med 42(5):643–647

    Article  PubMed  Google Scholar 

  26. 26.

    Amos SM, Duong CP, Westwood JA et al (2011) Autoimmunity associated with immunotherapy of cancer. Blood 118(3):499–509

    CAS  Article  PubMed  Google Scholar 

  27. 27.

    Hilbert G, Gruson D, Vargas F et al (2001) Noninvasive ventilation in immunosuppressed patients with pulmonary infiltrates, fever, and acute respiratory failure. N Engl J Med 344(7):481–487

    CAS  Article  PubMed  Google Scholar 

  28. 28.

    Rano A, Agusti C, Benito N et al (2002) Prognostic factors of non-HIV immunocompromised patients with pulmonary infiltrates. Chest 122(1):253–261

    Article  PubMed  Google Scholar 

  29. 29.

    Antonelli M, Conti G, Rocco M et al (1998) A comparison of noninvasive positive-pressure ventilation and conventional mechanical ventilation in patients with acute respiratory failure. N Engl J Med 339(7):429–435

    CAS  Article  PubMed  Google Scholar 

  30. 30.

    Wohlfarth P, Ullrich R, Staudinger T et al (2014) Extracorporeal membrane oxygenation in adult patients with hematologic malignancies and severe acute respiratory failure. Crit Care 18(1):R20

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This study was performed on behalf of the “Caring for critically ill immunocompromised patients—Multinational Network (Nine-I). This group includes critical care specialists from 16 countries in Europe, the USA, Canada and South America. The primary aim of this group is to improve and standardize practices in the management of critically ill immunocompromised patients.

Contributors: Antoine Rabbat, Hôpital Cochin, Paris, France; Isabelle Vinatier, CHD de Vendée, La Roche Sur Yon, France; Michael Darmon, CHU, Saint-Etienne, France; Kada Klouche, Laura Platon, CHU, Montpellier, France; Martine Nyunga, CHG Victor Provo, Roubaix, France; Alexandre Demoule, Julien Mayaux, CHU Pitié-Salpétrière, Paris, France; Florent Wallet, CHU, Lyon Sud, France; Akli Chermak, CH Sud Essonne, Etampes, France; Amelie Seguin Réanimation Medicale - CHU de Caen, Caen, France; Caroline Lemaitre, Elise Artaud-Macari, University Hospital, Medical Intensive Care, Rouen, France; Jonas Nelsen, Rigshospitalet, Copenhagen, Denmark; Ann M. Moeller, Herlev University Hospital, UCPH, Herlev, Denmark; Thomas Kaufmann, Department of Critical Care, Groningen, the Netherlands; Dennis Bergmans, Department of Critical Care, Maastricht, the Netherlands; Angélique Spoelstra de Man, Department of Critical Care, Amsterdam, the Netherlands; Ana Paula Pierre de Moraes, Hospital de Câncer do Maranhao, Brazil; William Viana, Hospital Copa d’Or, Brazil; Guilliana Moralez, Hospital GetulioVargas, Rio de Janeiro, Brazil; Thiago Lishoa, Hospital Santa Rita, Santa Casa de Misericordia, Porte Allegre, Brazil; Thiago Domingos Correa, ICU, Hospital Israelita Albert Einstein, São Paulo, Brazil; Belen Encina, Val Hebron, Barcelona, Spain; Gabriel Moreno, Department of Critical Care, Bellitge, Spain; Emilio Rodriguez Luis, Department of Critical Care, Santiago de compostella, Spain; Llorenç Socias Crespi, Department of Critical Care, Palma, Spain; Yadav Hemang, Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, USA; Anne-Pascale Meert, Institut Jules Bordet, Brussels, Belgique; Dominique Benoit, Ghent University Hospital, Ghent, Belgique; Nina Buchtele, Department of Medicine I, Vienna, Austria; Thomas Staudinger, Department of Medicine I, Vienna, Austria; Gottfried Heinz, Department of Medicine II, Vienna, Austria; Gürkan Sengölge, Department of Medicine III, Vienna, Austria; Christian Zauner, Department of Medicine III, Vienna, Austria; Peter Jaksch, Department of Thoracic Surgery, Vienna, Austria; Karin Amrein, Department of Internal Medicine, Graz, Austria; Aisling Mc Mahon, Department of Critical Care, St James, Dublin, Ireland; Brian Marsh, Department of Critical Care, Mater misericordia, Dublin, Ireland; Balik Martin, Department of Critical Care, Prague, Czech Republic; Karvunidis Thomas, Department of Critical Care, Pielsa, Czech Republic; Pål Klepstad, St. Olavs Hospital, Trondheim, Norway; Anne Kuitunen, Department of Critical Care, Tempere, Finland; Gilda Cinnella, Antonella Cotoia, Ospedali Riuniti, Department of Critical Care, Foggia, Italy; Sumech Shah, Mount Sinai Hospital, Canada.

Author information

Affiliations

Authors

Consortia

Corresponding author

Correspondence to Elie Azoulay.

Ethics declarations

Conflicts of interest

The authors declare no conflict of interest in relation to this study.

Additional information

The members of the Efraim investigators and the Nine-I study group are listed in the Acknowledgements and in ESM 2.

All authors substantially contributed to the design of the study, acquisition, analysis, and interpretation of data, drafted and revised the manuscript for important intellectual content, approved the final version, and agreed to be accountable for all aspects of the work.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOC 378 kb)

Supplementary material 2 (DOC 100 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Azoulay, E., Pickkers, P., Soares, M. et al. Acute hypoxemic respiratory failure in immunocompromised patients: the Efraim multinational prospective cohort study. Intensive Care Med 43, 1808–1819 (2017). https://doi.org/10.1007/s00134-017-4947-1

Download citation

Keywords

  • Noninvasive ventilation
  • High flow oxygen
  • Hematological malignancies
  • Transplantation
  • Systemic diseases
  • Pneumocystis